We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
-$88.1M
Cap. Flow %
-3.63%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Healthcare 13.39%
2 Energy 1.08%
3 Technology 0.46%
4 Materials 0.45%
5 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLYP
201
DELISTED
RELYPSA INC COM
RLYP
$1.29M 0.05%
+69,980
New +$1.92M
ADMS
202
DELISTED
Adamas Pharmaceuticals
ADMS
$1.28M 0.05%
+76,717
New +$1.75M
ABBV icon
203
AbbVie
ABBV
$471B
$1.28M 0.05%
+23,516
New +$1.53M
PCRX icon
204
Pacira BioSciences
PCRX
$1.04B
$1.28M 0.05%
+31,100
New +$1.9M
ATRS
205
DELISTED
Antares Pharma, Inc.
ATRS
$1.23M 0.05%
+722,567
New +$1.42M
ELGX
206
DELISTED
Endologix Inc
ELGX
$1.23M 0.05%
+10,000
New +$1.36M
ANTH
207
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.22M 0.05%
+250
New +$17.5K
VASC
208
DELISTED
Vascular Solutions Inc
VASC
$1.21M 0.05%
+37,296
New +$1.34M
LUMO
209
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.21M 0.05%
+3,740
New +$1.64M
BGMS
210
Bio Green Med Solution Inc
BGMS
$4.75M
$1.2M 0.05%
3
+1
+50% +$534K
ANAC
211
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$1.18M 0.05%
100
-239
-71% -$31.2K
ANAC
212
PUT
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$1.18M 0.05%
+100
New +$13.1K
POZN
213
DELISTED
POZEN INC
POZN
$1.17M 0.05%
+200,000
New +$1.96M
PVCT
214
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$1.14M 0.05%
1,982,137
-1,293,792
-39% -$663K
CRDF icon
215
Cardiff Oncology
CRDF
$60.1M
$1.14M 0.05%
+2,778
New +$1.45M
HALO icon
216
PUT
Halozyme
HALO
$9.85B
$1.13M 0.05%
840
– –
RDGT
217
Ridgetech Inc
RDGT
$842K
$1.12M 0.05%
+17
New +$1.39M
RXII
218
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$1.08M 0.04%
6,832
– –
REE
219
DELISTED
RARE ELEMENT RES LTD
REE
$1.08M 0.04%
3,843,873
-368,219
-9% -$139K
SAGE
220
CALL
DELISTED
Sage Therapeutics
SAGE
$1.06M 0.04%
+251
New +$15.5K
VTVT icon
221
vTv Therapeutics
VTVT
$124M
$1.05M 0.04%
+4,014
New +$1.4M
ADYX
222
DELISTED
Adynxx Inc
ADYX
$1.05M 0.04%
5,502
+3,002
+120% +$841K
HTWR
223
PUT
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1.04M 0.04%
+199
New +$15.1K
PGEN icon
224
CALL
Precigen
PGEN
$1.93B
$1.03M 0.04%
328
+1
+0.3% +$49
RCKT icon
225
Rocket Pharmaceuticals
RCKT
$332M
$1.03M 0.04%
+27,500
New +$1.26M
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.